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Abstract 
 
Chemical manufacturing is often done at large facilities that require a sizable capital investment and 
then produce key compounds for a finite period. We present an approach to the manufacturing of 
fine chemicals and pharmaceuticals in a self-contained plastic reactionware device. The device was 
designed and constructed by using a chemical to computer-automated design (ChemCAD) approach 
that enables the translation of traditional bench-scale synthesis into a platform-independent digital 
code. This in turn guides production of a three-dimensional printed device that encloses the entire 
synthetic route internally via simple operations. We demonstrate the approach for the g-
aminobutyric acid receptor agonist, (±)-baclofen, establishing a concept that paves the way for the 
local manufacture of drugs outside of specialist facilities. 
  
The manufacture of active pharmaceutical ingredients (APIs) is vital for modern health care, yet 
critical drugs are regularly manufactured for a finite period in a limited number of sites. The 
manufacture of chemical products—whether bulk, fine, or specialty chemicals, such as APIs—is 
currently based on a model whereby a central plant is exclusively designed for the manufacture of 
the product, or range of products, sold by that particular company (1). This model holds whether the 
manufacturer is a large pharmaceutical company or, as is increasingly the case, a contract research 
organization operating large chemical manufacturing plants to order from the pharmaceutical 
industry. This process leads to safety issues around both the storage and transport of such materials, 
as well as the issues inherent in the large-scale manufacture of chemicals (2). In addition, these 
large-scale plants are often at the mercy of complicated and global supply chains of raw materials, 
the failure of which at any point will reduce or halt the capacity of the plant to produce materials 
and deliver them effectively (3, 4). Also, when a given complex intermediate or API goes out of 
production, the plants are often repurposed and the manufacturing capacity is lost. The 
reinstatement of the process would require, in the best case, substantial capital investment to 
reconfigure a chemical plant for its synthesis. To alleviate this issue, we propose a concept whereby 
the large-scale manufacturing process of complex fine chemicals, such as APIs, is augmented by 
distributed, point-of-use manufacturing in self-contained cartridges, requiring limited user 
interaction to produce the desired products on demand. To achieve this, we developed a 
methodology for the translation of bench-scale synthesis procedures into a step-by-step workflow 
that could be used to create digital designs for custom reactionware that can be fabricated by using 
three-dimensional (3D) printing technologies. In this way, we aim to move beyond the preserve of 
industrial manufacturing and prototyping applications (5), to revolutionize the relationship between 
the design, manufacture, and operation of functional devices (6–11) and exploit the increasing use 
of 3D printing in the automation of the chemical sciences (12–15). This methodology, which is in 
stark contrast to both large- and medium-scale traditional chemical manufacture, and also to the use 
of continuous-flow and microreactor approaches (1, 16, 17), allows for the distribution of simple 
chemical precursors and solvents rather than the complex products themselves. These precursors 
could then continue to benefit from the economies of scale brought by traditional manufacturing 
processes while complex products with short shelf lives, or lower and more distributed demand, can 
be produced locally. This has added benefits in terms of manufacture of the final products as the 
synthesis of smaller quantities is inherently safer than large-scale processes and poses less risk to 
both operators and infrastructure. Further, the translation of these synthetic approaches into a 
digitally defined format, where the reactor design and, eventually, an automated synthesis 
procedure are encoded, could allow the digitization of all chemical products into a very low-cost 
manufacturing format. This could allow large numbers of discontinued APIs to be made available as 
they can be brought back into production on a small scale by the fabrication and use of the 
appropriate cartridges (18, 19). 
As a proof of principle, we present a process by which the traditional laboratory-scale synthesis of a 
commercially available API can be translated into the design of an integrated cartridge. To do this, all 
the reaction steps and intrasynthesis purification processes are encoded into the 3D architecture of 
the cartridge so that the chemical reactions, work-ups, and purification are done with minimal user 
intervention and exposure automatically. We have demonstrated this process in the full synthesis of 
the anticonvulsant medication (±)-baclofen (see below). 
This method for translating traditional laboratory syntheses into a form that can be encapsulated in 
a single cartridge is split into three layers of consideration, which were iteratively reevaluated during 
the cartridge development process. The first is the “conceptual layer,” where the chemical reactions 
and processes necessary are identified and developed. The second is the “digital layer,” in which 
these processes are translated into digital 3D models of the final cartridge devices. Finally, a 
“physical layer,” where the digital models are realized as either a modular implementation or a 
monolithic implementation, is used to generate the finalized cartridge, which can be used to effect 
the designed synthesis (Fig. 1). These physical systems can then be tested for efficacy as a final 
implementation, before iterating the process to develop reliable cartridge syntheses. 
 
Figure 1- Schematic representation of the translation of a multistep synthesis from conception through to 
implementation as a reaction cartridge. 
 Reactions necessary for the synthesis are identified (A→B→C→D, top left panel) and the specific chemical and physical 
processes and reaction parameters necessary for each reaction are laid out (conditions i. – iii., left panel). These processes 
are then translated into bespoke reaction modules designed to accomplish one or more of the chemical processes identified 
in the previous step (top right panel). The modules are then designed as 3D CAD models (lower center panel), with libraries 
of module components to accommodate the required reaction parameters. These digital models can then be fabricated to 
produce either a modular or monolithic implementation (lower right panel) of the process. 
First, the fundamental chemistry required for the transformations is considered and optimized to 
minimize the necessary interstep purification for the completion of the full synthesis. This approach 
is similar to that taken to develop telescoped (i.e., consecutive transformations in a single reactor or 
sequence of reactors without isolation and purification of intermediates) and “one-pot” syntheses 
(20, 21), often used in process chemistry, both of which aim to maximize the efficiency of the 
synthetic route. Although here it is not necessary to produce genuinely telescoped syntheses, as 
modules for interstep purification can be built into the cartridge design, the synthesis of the desired 
compound, including all reagents and starting materials for all the necessary steps, must be 
considered as a unified process. The choice of synthetic route to any target compound will be 
dictated by a number of factors, including the relative availability and cost of starting materials, 
reagents, and solvents, as well as the compatibility of reaction and purification sequences with the 
reactor modules produced. In any wide-scale application of our approach, a cost analysis of any 
proposed synthetic route will have to be performed to ensure its viability for the product. Once the 
chemistry for the synthesis is developed, a sequence can be produced where the physical processes 
and reaction parameters—such as heating, cooling, phase separations, reaction volumes, and 
times—can be identified. 
Vital to the success of these modules is the compatibility of the cartridge material with the chemistry 
being performed. Whereas traditional laboratory syntheses take place mostly in glassware, we use 
polypropylene (PP) as a basic structural material for the fabrication of the cartridges. We have found 
that this polyolefinic material, while demonstrating a robust range of chemical compatibility for 
traditional synthetic organic reactions, is also a suitable substrate for 3D printing applications (22–
24). This gives the best balance of chemical resistance and material properties for 3D printing. 
Therefore, the first step in the design process is testing the reactions necessary for compatibility in 
the reactor materials. Future iterations of the concept could expand on the materials and fabrication 
processes available for the reaction modules to further develop the range of chemistries feasible in 
this system, using, for example, perfluorinated polymers to increase the chemical resistance of the 
module. 
To demonstrate the feasibility of incorporating these PP reactors into the production of APIs, we 
tested a number of reactions that lead to such targets in test modules fabricated from PP (Fig. 2). 
We tested reactions for the synthesis of three APIs: the central nervous system inhibitor (±)-baclofen 
(25), the anticonvulsant lamotrigine (26), and the gastroprotective agent zolimidine (27). As can be 
seen, all of the reactions tested were observed to work, but with slightly lower efficiency in PP 
reactors than in traditional glass reactors, owing to physical loss of material on the relatively rough 
PP surface hampering product recovery. Surface roughness is inherent in the 3D printed process; 
however, use of other, as yet undeveloped, materials or different manufacturing techniques could 
reduce this issue. The zolimidine reactions, particularly the copper-catalyzed iodination reaction, 
experienced a pronounced reduction in efficiency, compared to (±)-baclofen or lamotrigine. We 
surmised that this was due to side reactions of the iodine with the polypropylene. These issues 
highlight that the process of translation from glassware must take into account both the physical and 
chemical properties and limitations of the reactor substrate (23). For this reason, the first two 
syntheses were selected for further development into reaction cartridges to explore the concept. 
 
Figure 2- Comparison of glass reactors with plastic reactionware for the optimized synthetic routes to (±)-baclofen (top), 
lamotrigine (middle), and zolimidine (bottom) with reaction yields for each step (reaction yields in PP vessels given in 
parentheses).  
Single (top right) or double (bottom right) chambered polypropylene reaction test cartridges were used. PP, polypropylene; 
TBAF, tetrabutylammonium fluoride; THF, tetrahydrofuran. 
Once the processes needed for the reaction sequence are identified, the combined continuous 
protocol is mapped onto the 3D digital designs for the target-specific cartridge. The sequence of 
processes is split into a series of modules, with each representing a telescoped series of processes 
that can take place in a single chamber of the 3D printed system. Each process module is then 
created as a digital model that can be manipulated to provide the correct physical dimensions 
necessary for the reaction scheme. The 3D models of the cartridges used in this study were created 
with OpenSCAD software, an open-source framework for CSG (constructive solid geometry) 
modeling that allows a highly flexible and configurable approach to create versatile libraries of 
components as reusable pieces of code. Once defined, these pieces of code can be manipulated by 
the software, allowing the generation of complex reactor geometries with minimal human inputs. 
For example, in this study, we designed a module library consisting of interchangeable top and 
bottom components with varying features that can be easily combined to produce reaction vessels 
with different shapes and features. From a single line of code, an entire module can be created, with 
18 different shapes available (i.e., three different tops and six different bottoms can be selected; Fig. 
3). The modules were designed around simple chambers where each reaction or process could be 
performed in as close a manner as possible to the way it would be carried out with traditional batch 
chemical techniques, easing the transition between published synthesis in glassware and “cartridge” 
synthesis. Typically, a standard module would have an opening on the top of the wall of the chamber 
for transfer of reaction mixtures from previous modules and an opening at the bottom of the 
chamber for expelling material from the module subsequent to the completion of the desired 
process. The transfer of material between modules is facilitated by a further opening in the roof of 
the compartment, which can be used to apply pressure that forces the reaction medium out of the 
chamber via the outlet at the bottom. The opening at the top otherwise equalizes pressure 
throughout the device to prevent the premature transfer of material, and also allows for application 
of vacuum to remove and exchange solvents. These modules can then be combined in sequences by 
use of further components of our module library such as siphon tubes for the transfer of material 
from one reaction module to another. 
 
Figure 3- Parameterized approach to the design of individual process modules.  
Digital libraries of module components (top) can be easily assembled to produce a wide range of module geometries 
dictated by the specific process and reaction parameters (e.g., solvent volumes, number of inputs and outputs, etc.) 
(bottom). Hydrophobic filters for phase separation are shown in red, and fritted glass filters are shown in blue. DCM, 
dichloromethane. HR, reactor height. 
Once a reaction chamber is created, new features can be introduced by subtracting or adding shapes 
to the module. For example, a filtration device can be made from a module with a top input, a round 
bottom with a port, and a glass filter. To achieve this feature, a cylindrical model conforming to the 
dimensions of the physical filter to be inserted is created and subsequently subtracted from the 
model of a reaction chamber, producing a void space in the model into which the filter fits (see 
supplementary materials). Phase separation modules were achieved in a similar manner by using 
hydrophobic frit inserts that effectively separate organic and aqueous phases for product 
extractions. In keeping with our desire to design synthesis cartridges that can be produced outside 
traditional manufacturing regimes, we have exploited our group’s development of 3D printed 
reactors—reactionware—for synthetic chemical applications as a method of prototyping the 
physical reactors (28, 29). Three-dimensional printing–based fabrication approaches have the added 
advantage of being intimately linked to the design process. 
Fabrication of the modular system was carried out on low-cost (~$2000) 3D printers, Ultimaker 2 
and 2+, although many other fused deposition modeling (FDM) printers could print the 3D modules 
produced through this approach. If it is necessary to incorporate nonprinted materials during 3D 
printing of the final module, a preprogrammed pause in the printing process is instigated at a point 
just above the designed void, and the component is inserted in this space before the resumption of 
printing. Upon completion of printing, the inlet and outlet ports were tapped with a ¼ inch unified 
national fine (UNF) thread to allow ease of integration with the external infrastructure for 
performing the reaction sequences. Using standard ports allowed us to attach either standard fluidic 
tubing connectors such as those found in traditional flow synthesis setups, or widely used Luer lock 
adapters. These Luer lock connectors are easily reconfigurable, facilitating feedback into the design 
process. 
The API chosen to accomplish a complete end-to-end synthesis was the central nervous system 
depressant and antispastic medication (±)-baclofen (30, 31) [RS-β-(4-chlorophenyl)-γ-aminobutyric 
acid] (4) (Fig. 4), a derivative of γ-aminobutyric acid (GABA) that modulates the action of this central 
inhibitory neurotransmitter (25). This target was chosen as an example to demonstrate that even 
relatively short syntheses require a disproportionately larger set of chemical processing steps to 
effect the full synthesis; in the future, we envision that the synthesis of larger numbers of 
compounds and compound classes will greatly expand the scope of this approach. (±)-Baclofen has 
found a number of applications since its first reported synthesis and is currently being investigated 
beyond its traditional use, as a high-dose treatment for alcoholism (32). Many syntheses of (±)-
baclofen have been published since it was first reported, often proceeding through the formation, 
and subsequent hydrolysis, of β-(4-chlorophenyl)-γ-butyrolactam (3). We have modified such a 
traditional synthesis of (±)-baclofen starting from the commercially available material methyl 4-
chloro-cinammate (1), and proceeding via the Michael addition of nitromethane to form 4-nitro-3-
(4-chlorophenyl)butanoic acid (2), followed by nickel-catalyzed reductive lactamization and 
subsequent acid hydrolysis to produce the final product in its commercially available racemic form as 
a hydrochloride salt. This three–reaction-step sequence contains 12 individual processing steps that 
must be incorporated into the reactionware device to complete the synthesis (Fig. 4). This sequence 
was designed to be particularly amenable to translation into the modular or monolithic system as at 
each stage, the reactions are either sufficiently clean, or reaction impurities that would impinge on 
subsequent process in the synthesis could be readily removed by phase partition. The final product 
is purified through a methanol–diethyl ether crystallization, which yields a crystalline solid that can 
be retrieved directly from the cartridge device. An animation of the entire process, showing the 
passage of reagents, processes, and work-ups, is shown in movie S1. 
 
Figure 4- Synthesis of (±)-baclofen in a series reaction cartridges.  
(Top) Conceptual synthetic procedure for the synthesis of (±)-baclofen under the conditions described in Fig. 2, showing the 
necessary processing sequence to effect this synthetic pathway. These processes were then split into modules (a) to (e) 
(indicated by gray boxes in the process sequences), which we translated into a digital design (middle left) and finally 
fabricated as either a modular (middle right) or monolithic (bottom left) implementation. A partially fabricated monolithic 
cartridge is also shown indicating the placement of non-3D printed components and internal fluidic pathways (bottom 
center and right). Both modular and monolithic cartridges are shown with Luer taper–compatible valving for interfacing 
with external fluidic inputs and pressure or vacuum lines. 
Each of these processes was translated into operations that could be successfully embodied in one 
or more reaction or purification modules. The specific reaction modules used for the synthesis of (±)-
baclofen were (a) a combined Michael addition, evaporation and ether extraction module; (b) a 
combined solvent exchange and reduction module; (c) a phase separation and filtration module; (d) 
a combined solvent exchange and hydrolysis module; and (e) a filtration module. Individual modules 
were fabricated for a “plug-and-play” approach to the reaction process development by using Luer 
lock fittings to connect individual modules and Luer taper–compatible valves to interface with 
pressure or vacuum systems. This design allowed testing of each individual process in isolation 
before the modules were combined to build up the full synthesis. Finally, the module designs were 
“digitally stitched together” by using the developed CAD libraries for internal fluidic pathways to 
create the design for a monolithic synthesis cartridge. Once fabricated, the individual modules and 
the monolithic cartridges were evacuated and filled with a nitrogen atmosphere to ensure an inert 
environment for the subsequent chemistry. 
The first chamber, (a), consists of a lower volume (4.9 ml) where the initial reaction can take place 
and is separated from the upper outlet by a hydrophobic frit. Reactor modules (b) and (d) consist of 
a single unbroken reaction chamber (31.8 ml) with sufficient volume to accommodate the reaction 
volumes and extraction solvents from the previous processes before concentration under reduced 
pressure. Extraction module (c) consists of a chamber of sufficient volume (4.7 ml) to contain the 
aqueous phase from the previous chamber, which has a drain at the bottom covered by a 
hydrophobic frit that prevents both solid material and aqueous solution from passing into the next 
chamber or module. The final module is a filtration module for separating and retrieving the final 
product. This single module can be either open to the atmosphere or enclosed as required. During 
the fabrication process, chambers or modules that required stirring were equipped with a PTFE 
(polytetrafluoroethylene)–coated magnetic stirring bead (length 10 mm) to enable mixing of the 
contents. Each module or chamber of the monolith was equipped with a ¼ inch UNF threaded port 
carrying a female Luer lock adapter, which was used to introduce an inert (dry, N2) atmosphere, or 
reduced pressure, into the system. The modular system was designed such that there was a single 
fluidic path through the reactor; flow from one chamber into the next was induced either by 
pressure from excess solvent, in the case of the phase separation processes, or the introduction of 
nitrogen pressure difference between the relevant chambers to push the reaction mixture through 
an embedded channel running from the bottom of one chamber to the top of the next. 
Starting materials were prepared as simple solutions and transferred to the cartridge via standard 
Luer syringes. The cooling and heating required for the reaction sequence were achieved by the 
immersion of the reaction cartridge or module in an ice or sand bath, respectively, and the 
temperature required for the reactions can be achieved automatically on a stirring-hotplate. The 
exact sequence of operations, positioning of the module in the heating or cooling bath, and time 
intervals necessary for completing the synthesis are outlined in the supplementary materials (figs. 
S12 and S13 and table S3). 
Performing the synthesis starting from 200 mg of 1 in the manner described yielded 98 mg (39% 
yield over three reaction steps and 12 processing steps from 1 with ≥95% purity as determined by 
high-performance liquid chromatography) of (±)-baclofen hydrochloride salt, which is more than 1 
day’s maximum dosage of the drug. Better efficiency of reaction can be achieved with lower 
concentrations of starting materials (using a similar cartridge at half concentration, i.e., 100-mg 
scale, gave a 44% yield over three steps of similar purity). Increasing the volume of the reactor as 
well increases the quantity of (±)-baclofen obtained [a 300-mg scale synthesis yielded 133 mg (35%) 
(±)-baclofen]. The integration of the reaction processing steps into the design of the modules greatly 
simplifies the operations required to perform the reaction sequence compared to traditional bench 
synthesis and simultaneously reduces the level of technical skills required to perform the process 
down to simple operations that do not require the specific skills of a trained synthetic chemist. 
Although the total time for the reaction sequence is around 40 hours in this case, including all 
intermediate operations, the workflow is constrained by the geometry of the device, so all human 
interaction is limited to simple interventions at specific time periods, and it should be possible to 
shorten the interaction time further. The use of such bespoke, single-use cartridges would greatly 
reduce the time spent on glassware preparation, liquid handling, and other ancillary tasks associated 
with the majority of chemical syntheses at this scale. Also, by using the geometry of the reactor to 
constrain the operation of the synthesis, we reduce the human decision making involved in the 
synthesis processes, making the sequence more reproducible. Given sufficient facilities, several 
instances of the synthesis cartridge could be used at once, achieving scalability by numbering-up 
arrays of cartridges, and using these in parallel to increase the output. As a result of the ability to 
parameterize and encode multistep organic synthesis reactions with work-ups embedded, we 
envisage that a digital programmable universal heater-stirrer-solvent-reagent plug-and-play device 
can be constructed into which only the cartridge, specific to a given synthesis, can be plugged in. 
The (±)-baclofen synthesis necessitated liquid handling and separation of reaction chambers to 
effect the full reaction sequence. In some cases, however, syntheses can be conducted in single 
reaction cartridges, depending on the nature and quality of the interstep purification required. For 
example, the synthesis of lamotrigine (Fig. 2) can be achieved in a single cartridge as the 
intermediate material is insoluble in the reaction solvent at low temperatures. In a single, closed, 
filtration module, the initial reaction product could be washed and processed in situ before 
introduction of the solvent for the subsequent cyclization step. This stands in contrast to the 
traditional procedure, which requires the solid product of the first step to be removed from the 
initial reactor to be filtered, dried, and then reintroduced to a reactor for the second step of the 
synthesis. Performing the synthesis of lamotrigine on a 250-mg scale of starting material yields 112 
mg (46% over two reaction steps) of the final product, giving an off-white crystalline powder. 
The digital approach to the design of the system that we have adopted allows the blueprints for 
these cartridges to be stored electronically for implementation as and when required. The 
distribution model for fine and specialty chemicals, such as the APIs implied by this approach, would 
lead to a decentralizing of logistical approaches to chemical manufacture. Here, any location with 
access to a sufficiently diverse market of chemical precursors and suitable cartridge fabrication 
facilities could be used to produce chemical products, which could previously be achieved only in a 
fully equipped synthesis laboratory with highly trained staff. This approach not only holds promise 
for eventually delivering on-demand personalized medicines manufactured at, or near, the point of 
use, but also has short-term potential applications in the synthesis of APIs that are currently out of 
production. An immediate impact of digitization is that the cost for synthesis at the bench scale 
(milligrams) could decrease markedly owing to savings in labor and infrastructure with only a one-off 
digitization cost (and allow operators to make 5 to 10 different products at the same time). Once the 
saving meets the digitization cost, the efforts of the expert chemist will shift from bespoke on-
demand chemical manufacturing to chemical digitization (see supplementary materials for an 
economic analysis). Our methodology will have the most rapid impact for chemicals that are 
currently produced on demand in small batches and that occupy a gap in the market where the 
demand for a product is sufficient for it to be commercially viable but insufficient to justify plant-
scale production. This gap lies between the high cost of bench-scale versus reactor-scale synthesis, 
and thus the digitization benefit of compounds in this zone is high. 
The regulatory framework necessary to produce complex materials in this fashion will need 
thorough attention; indeed, our approach would require a completely new system for the regulation 
of API manufacture. This system would have to be developed alongside the evolution of this 
approach as a method for pharmaceutical synthesis, which we have presented here in proof-of-
concept form; however, we can envision a situation in which regulatory agencies certify specific 
cartridge or module designs as soon as a digitized process is fully established (including the 
embedded quality-control protocols), independent of the physical location of person who uses the 
cartridge. This approach has multiple benefits. First, the framework can adopt well-established 
methods of digital object certification from the information technology universe (e.g., digital signing 
with asymmetric ciphers). Second, no explicit certification would be needed for each new “facility” 
(which might be a hospital or a private house) that would need the drug. Third, existing methods for 
protecting and manipulating digital content provide much more efficient models for distribution and 
regulation compared to the retail and patent system, respectively. These regulatory issues 
surrounding the commercial or clinical application of this approach are not trivial, and care must be 
taken to ensure that end-user safety is not compromised. However, we believe that the benefits in 
terms of efficiency of delivery, robustness of supply, and range of materials available could lead to 
the digitization of chemical synthesis. 
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